Our History

While there were numerous spinal fusion product companies and several that operated in the neurostimulation market, none had the vision to combine the two therapy modalities of spinal fusion and neuromodulation into a single solution implanted simultaneously at the point of a spinal fusion procedure.

In 2018, SynerFuse™ was co-founded by Dr. Nazmi Peyman, pain physician, Dr. Greg Molnar, Ph.D., former Chief Science Officer, a deeply experienced neurostimulation scientist, and Justin Zenanko, CPA, MDiv, Chief Executive Officer. In 2018, under Company’s leadership, the company identified an enormous whitespace opportunity and built a deep and broad intellectual property portfolio around it. Dr. Molnar, together with Dr. Peyman, Mr. Zenanko and fellow co-inventors, created the SynerFuse™ solution of integrated spinal fusion and neuromodulation.

2022, SynerFuse™ e-TLIF™ patented procedure was performed by Michael Park, MD, PhD and Rohan Lall, MD at the University of Minnesota. In 2023 Rohan Lall performed the world’s first solo procedure in the world and has completed 11 of 15 e-TLIF™ procedures.

The SynerFuse™ team is experienced in growing startups and building value for shareholders and is composed of experts in spine surgery, product development, and intellectual property. SynerFuse partners with experts in FDA regulation. The Management Team, Board of Directors, Medical Advisory Board and Strategic Advisors work each day to deliver better patient outcomes and maximize shareholder return. 

The Spinal Fusion Market and Pain Management Opportunity

There are more than 570,000 spinal fusion procedures performed annually in the United States alone. And the market is expected to grow steadily based on our aging population and the high obesity rates. As many as 40% of cases result in chronic, residual pain following a spinal fusion surgery costing the US healthcare system $20B annually. A common treatment pathway is a narcotic-based regimen. If that is not successful, neurostimulation is sought in a two-step process: a trial and a final implant, thus subjecting a patient to three surgical procedures. In contrast, the SynerFuse™ approach involves the combined implantation of a spinal fusion device and our SynerFuse™ device concept.

SynerFuse™ Milestones

Company completed enrollment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™) procedure integrating spinal fusion with direct nerve stimulation, which is designed to treat neuropathic chronic low back pain (cLBP). The company will prepare for a national clinical trial utilizing a custom-built NeuroFuse e-TLIF™ LE spinal fixation/electronic neuromodulation device. Concurrent with this activity, SynerFuse™ will be continually building out its intellectual property portfolio, and implementing regulatory and reimbursement strategies.